Mono Vaccines (Epstein - Barr virus) Market Advancements to Watch Out For 2026

Mononucleosis also known as mono or kissing disease is an infectious illness caused by Epstein-Barr virus. This virus is generally spread through saliva hence, commonly called as kissing disease. It can also be spread through other ways such as sharing drinks or utensils.

Epstein-Barr virus also known as human herpesvirus 4 is the causative agent of mono/ kissing disease. Epstein–Barr virus is the most common type of virus in humans and is one of eight known human herpes virus types in the herpes family. According to the data published by Fred Hutchinson Cancer Research Center in 2018, Epstein–Barr virus infects about 9 out of 10 people globally at some point in their lives

According to study published by Fred Hutchinson Cancer Research Center in 2018, Epstein - Barr virus is the first virus, which can cause cancer in humans. According to same source, Sun Yat-Sen University Cancer Center in China estimated around 5,000 cases of nasopharyngeal carcinoma in a year due to Epstein - Barr virus.

Diagnosis of Epstein - Barr virus is difficult as its symptoms are very similar and common as other illness. This virus can be confirmed by blood test, which detects antibodies. Currently, there is no licensed or approved vaccine available for Epstein - Barr virus. However, various research organizations and companies are focusing on research activities for the development of vaccines against Epstein-Barr virus.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/2002

Mono Vaccines (Epstein - Barr virus) Market Drivers

Increasing research and development activities by various universities and companies for development of novel Mono Vaccines or Epstein - Barr virus vaccines is expected to fuel global mono vaccines (Epstein - Barr Virus) market growth in the near future. For instance, in April 2018, Researchers from Fred Hutchinson Cancer Research Center and the University of Washington developed a human antibody in laboratory tests that blocks infection by mono Epstein-Barr virus, or EBV.

Since 2017, University of Kansas School of Engineering and School of Pharmacy is studying genetics of human immune responses to produce a potent vaccine for Mono, Epstein - Barr virus, or EBV. Such increasing research activities by various organizations for development of novel vaccines for EBV will lead to the global mono vaccines (Epstein - Barr virus) market growth.

Furthermore, funding raised by various organizations to support the development of novel EBV vaccine is also expected to create a lucrative environment for mono vaccines (Epstein - Barr virus) market growth in the forecast period. For instance, in 2017, University of Kansas School of Engineering and School of Pharmacy received US$ 1.8 million, five-year grant form National Institutes of Health for conducting research to develop an effective vaccines for EBV.

High prevalence of Epstein - Barr virus is expected to increase demand for its vaccines and this is expected to drive the mono vaccines (Epstein - Barr virus) market growth in the near future. For instance, according to data published by National Center for Biotechnology Information in 2015, Epstein–Barr virus is the most common type of virus and globally, over 95% of adults are infected with EBV. According to the same source, it was estimated that in Africa around 50% of the children are infected before 1 year of age.

Mono Vaccines (Epstein - Barr virus) Market Regional Analysis

North America is expected to hold a dominant position in global mono vaccines (Epstein - Barr virus) market over the forecast period. This is owing to increasing research and development activities by various organizations present in the region. For instance, in 2015, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, with other partners developed a nanoparticle-based vaccine against EBV. This novel vaccine can produce powerful neutralizing antibodies in vaccinated mice and non-human primates.

Asia Pacific mono vaccines (Epstein - Barr virus) market is expected to exhibit a good growth in the near future, owing to increasing prevalence of Epstein - Barr virus in the region. For instance, according to data published by Fred Hutchinson Cancer Research Center, in 2018, Epstein - Barr virus is one of the most common virus and caused most cancer cases and cancer deaths in southern China and Southeast Asia. It caused around 10% of gastric cancers and about 100% of nasopharyngeal carcinomas in the region.

Request for Discount Before Buying This Business Reports @ https://www.coherentmarketinsights.com/insight/request-discount/2002

Mono Vaccines (Epstein - Barr virus) Market Key Players

Key players operating in global Mono Vaccines (Epstein - Barr virus) market include, GlaxoSmithKline Plc., Henogen SA, and others.

Mono Vaccines (Epstein - Barr virus) Market Taxonomy:

The global mono vaccines (Epstein - Barr virus) market is segmented on the basis of age group, and region

By Age Group-

Adult
Pediatrics
By Region-

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.